These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 14962729

  • 1. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
    Walker J, Martin C, Callaghan R.
    Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729
    [Abstract] [Full Text] [Related]

  • 2. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, Gu LQ, Yang XP, Fu LW.
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [Abstract] [Full Text] [Related]

  • 3. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
    Chen G, Waxman DJ.
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
    [Abstract] [Full Text] [Related]

  • 4. Drug resistance in chemotherapy for breast cancer.
    Saeki T, Tsuruo T, Sato W, Nishikawsa K.
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH.
    Life Sci; 2008 Nov 21; 83(21-22):700-8. PubMed ID: 18845169
    [Abstract] [Full Text] [Related]

  • 7. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.
    Cancer Chemother Pharmacol; 2006 Nov 21; 58(5):640-53. PubMed ID: 16544145
    [Abstract] [Full Text] [Related]

  • 8. Differential changes in purine nucleotides after Doxorubicin treatment of human cancer cells in vitro.
    Walenta S, Feigk B, Wachsmuth I, Dunkern T, Degani H, Mueller-Klieser W.
    Int J Oncol; 2002 Aug 21; 21(2):289-96. PubMed ID: 12118323
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
    Liu ZL, Hirano T, Tanaka S, Onda K, Oka K.
    J Pharm Pharmacol; 2003 Nov 21; 55(11):1531-7. PubMed ID: 14713364
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effect of steroidal alkaloids on drug transport and multidrug resistance in human cancer cells.
    Lavie Y, Harel-Orbital T, Gaffield W, Liscovitch M.
    Anticancer Res; 2001 Nov 21; 21(2A):1189-94. PubMed ID: 11396162
    [Abstract] [Full Text] [Related]

  • 12. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX, Yang XH.
    Yao Xue Xue Bao; 2008 May 21; 43(5):461-6. PubMed ID: 18717331
    [Abstract] [Full Text] [Related]

  • 13. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
    Abulrob AN, Mason M, Bryce R, Gumbleton M.
    J Drug Target; 2000 May 21; 8(4):247-56. PubMed ID: 11144235
    [Abstract] [Full Text] [Related]

  • 14. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids.
    Xing H, Wang S, Weng D, Chen G, Yang X, Zhou J, Xu G, Lu Y, Ma D.
    Oncol Rep; 2007 Jan 21; 17(1):117-22. PubMed ID: 17143487
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P.
    Cancer Res; 2001 Jan 15; 61(2):749-58. PubMed ID: 11212278
    [Abstract] [Full Text] [Related]

  • 16. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W, Li Y, Cai Y, Kang K, Yan F, Liu G, Huang W.
    J Pharm Pharmacol; 2007 Dec 15; 59(12):1649-55. PubMed ID: 18053326
    [Abstract] [Full Text] [Related]

  • 17. Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells.
    Muir CP, Adams MA, Graham CH.
    Breast Cancer Res Treat; 2006 Mar 15; 96(2):169-76. PubMed ID: 16331349
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
    Chavanpatil MD, Patil Y, Panyam J.
    Int J Pharm; 2006 Aug 31; 320(1-2):150-6. PubMed ID: 16713148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.